中文

康泰生物 Revenue Breakdown

Period 2026-03-31 ・ Reported 2026-04-22
ItemAmountY/Y
Revenue¥0.63B-2.2%
Gross profit¥0.45B
Operating income¥0.04B
Net income¥0.03B+50.1%
Gross margin71.1%Net margin 5.3%
Revenue Q/Q+3.5%

Revenue Segments

The filing did not disclose a revenue breakdown for this period.

Costs & Expenses

ItemAmount% of revenue
Cost of revenue¥0.18B28.9%
R&D¥0.08B13.4%
SG&A¥0.30B48.0%
Tax & other¥0.01B1.1%
Generate the full Sankey chart →

The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.

Other companies

飞荣达立昂技术长川科技恒锋信息金太阳拓斯达思特奇汇纳科技晨化股份美力科技宣亚国际富瀚微

Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies